Switching Between Generic and Brand-Name Antiepileptic Drugs


In this video interview filmed at ECTRIMS 2013, Daniel Kantor, MD, medical director of Neurologique and immediate past president of the Florida Society of Neurology, discusses the risks of switching epilepsy patients between generic and brand-name antiepileptic drugs.
Though going generic can reduce prescription costs, Kantor says sometimes generic medications don’t make sense for epileptic patients with stable response to brand-name medication — not because the generic medication is inadequate, but because of “the fluctuations when people go from one generic to another.”
Kantor cites one study on topiramate that kept one group of patients on Topamax, switched another group to Teva Pharmaceutical Industries’ generic version of the drug, and gave a third group topiramate from different generic manufacturers each day, which is what typically happens at pharmacies. According to Kantor, patients who had that “real world experience” with varying generic manufacturers had breakthrough seizures, while patients who stayed on one version of the antiepileptic drug didn’t have those seizures.
“Breakthrough seizures are dangerous — they can even be deadly — and in many states, people are not allowed to drive after having had a seizure. And so that means that we want to try to avoid our patients with epilepsy having any more seizures,” Kantor says. “Once a patient is stable on a medication, it probably makes sense for them to stay on that.”

Most Popular

Recommended Reading

The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the US Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.
Treating patients with migraines and psychiatric comorbidities can require a delicate balancing act of medications and other forms of therapy.
In many cases helping patients manage their migraine headaches can prove to be enough of a challenge. Adding psychiatric conditions to the diagnosis can further complicate the treatment process for doctors.
Football helmet add-ons may not reduce players' risk of concussion, according to a new study scheduled for presentation at the upcoming annual meeting of the American Academy of Neurology, to be held from April 18 to 25 in Washington, DC.
$vacMongoViewPlus$ $vAR$